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Abstract  
Objective: In ageing men, the incidence and clinical significance of testosterone (T) decline 
accompanied by elevated luteinising hormone (LH) are unclear. We describe the natural 
history, risk factors and clinical features associated with the development of biochemical 
primary hypogonadism (PHG, T<10.5nmol/L and LH>9.4U/L) in ageing men. 
Design, Patients and Measurements: A prospective observational cohort survey of 3,369 
community-dwelling men aged 40-79 years, followed up for 4.3 years. Men were classified 
as incident (i) PHG (eugonadal [EUG, T≥10.5nmol/L] at baseline, PHG at follow-up), 
persistent (p) PHG (PHG at baseline and follow-up), pEUG (EUG at baseline and follow-up) 
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and reversed (r) PHG (PHG at baseline, EUG at follow-up). Predictors and changes in 
clinical features associated with the development of PHG were analysed by regression 
models. 
Results: Of 1,991 men comprising the analytical sample, 97.5% had pEUG, 1.1% iPHG, 
1.1% pPHG, and 0.3% rPHG. The incidence of PHG was 0.2%/year. Higher age (>70 years) 
[OR 12.48 (1.27-122.13), p=0.030] and chronic illnesses [OR 4.24 (1.08-16.56); p=0.038] 
predicted iPHG. Upon transition from EUG to PHG, erectile function, physical vigour and 
haemoglobin worsened significantly. Men with pPHG had decreased morning erections, 
sexual thoughts and haemoglobin with increased insulin resistance.  
Conclusions: Primary testicular failure in men is uncommon and predicted by old age and 
chronic illness. Some clinical features attributable to androgen deficiency, but not others, 
accompanied the T decline in men who developed biochemical PHG. Whether androgen 
replacement can improve sexual and/or physical function in elderly men with PHG merits 
further study. 
 
Introduction 
 
Low circulating testosterone (T) concentration is common in ageing men, increasing in 
prevalence from 20% to 50% between 60-80 years of age1, but only a very small proportion 
develops symptomatic hypogonadism. In the European Male Ageing Study (EMAS) of 40-79 
year-old community-dwelling men, the prevalence of low T (<10.5nmol/L) was 13.8%2, but 
hypogonadism (defined by low T with 3 cognate symptoms) could be identified in only 
2.1%3. Others have also found a significantly lower prevalence of symptomatic 
hypogonadism compared to that of biochemical hypogonadism (low T)4. Conspicuously, low 
T and putative hypogonadal symptoms are seldom detected in the same men, highlighting 
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their tenuous association and the substantial overlap between features of hypogonadism and 
those of ageing and chronic illness2,4. Utilising changes in the tightly regulated feedback 
relationships in the hypothalamic-pituitary-testicular (HPT) axis, by combining 
gonadotrophin with T measurements, may enhance the precision of detecting, or predicting 
the advent, of unequivocal androgen deficiency in ageing men. 
 
Biochemical hypogonadism can be divided into primary hypogonadism (PHG, elevated 
gonadotrophin level, testicular defect) and secondary hypogonadism (SHG, low or 
inappropriately normal gonadotrophin level, hypothalamic-pituitary defect)2. Cross-sectional 
analyses of EMAS baseline data found PHG to be strongly associated with higher age, but 
not obesity, while SHG was predominantly found in connection with obesity, and was 
independent of age2,5. In the present study, we report, for the first time, prospective 
observational data regarding the predisposing factors and clinical features of men who 
developed PHG. 
 
Methods 
 
Participants and study design 
The study design (including the assessments described below in “Other measures”) and 
recruitment strategy for EMAS have been described previously6,7. Briefly, an age-stratified 
sample of 3,369 men aged 40–79 (mean ±SD: 60 ±11) years was recruited from population 
registers in eight European centres. Participants were assessed on two occasions separated by 
a median of 4.3 (range 3.0-5.7) years. Ethical approval for the study was obtained in 
accordance with local requirements in each centre. All participants provided written informed 
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consent. For this analysis, participants with disease of the pituitary, testes or adrenal glands 
and participants on medications known to affect androgen levels were excluded. 
 
Hormone measurements 
A single fasting morning (before 1000) blood sample was obtained at baseline and follow-up. 
T was measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS)8, with 
paired baseline and follow-up samples analysed simultaneously. LH, FSH and SHBG were 
measured by the E170 platform electrochemiluminescence immunoassay (Roche 
Diagnostics). The Vermeulen formula was used to calculate free (f) T9. Intra- and inter-assay 
coefficients of variation (CV) were: T 4.0 and 5.6%; LH 1.9 and 2.7%; FSH 0.9% and 1.9%; 
and SHBG 1.9 and 3.2%. Insulin was assayed using chemiluminescence (CVs: 3.9% and 
5%). Insulin resistance was calculated using the homeostasis model assessment of insulin 
resistance (HOMA-IR)10.  
 
Biochemistry/haematology 
Standardised measurements were undertaken in laboratories in each centre. 
 
Other measures 
Participants answered questions about: smoking, alcohol consumption frequency and specific 
illness. A participant was considered to have a chronic illness if he had one (or more) of the 
following self-reported illnesses: heart problems, stroke, hypertension, diabetes, bronchitis, 
cancer, kidney disease or liver disease. Participants also completed quality of life 
questionnaires, which included ratings of general health (MOS 36-item Short-Form health 
survey [SF-36]), depression [Beck’s Depression Inventory (BDI)], physical activity [Physical 
Activity Scale for the Elderly (PASE)] and sexual symptoms (EMAS Sexual Function 
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Questionnaire). As described previously, participants were dichotomised to symptomatic or 
asymptomatic according to pre-specified responses associated with differences in T levels3. 
Body weight and height were measured by electronic scale and stadiometer (SECA UK). 
Physical function was assessed by Reuben’s Physical Performance Test (PPT) and cognitive 
processing speed by Wechsler’s Digit-Symbol Substitution test (DSST).  
 
Gonadal status 
Participants were assigned gonadal status according to total T and LH levels. Current 
guidelines recommend use of total T rather than free T to define hypogonadism11,12. Men 
with a T≥10.5 nmol/L were considered eugonadal (EUG) and men with a T<10.5 nmol/L and 
a LH>9.4 U/L were considered to have primary hypogonadism (PHG)2. Subjects were 
categorised further by their change in gonadal status into one of four groups: (1) persistent 
(p) EUG – EUG at baseline and at follow-up; (2) incident (i) PHG - EUG at baseline and 
PHG at follow-up; (3) persistent pPHG - PHG at both baseline and follow-up; and (4) 
reversed (r) PHG - reversal of PHG at baseline to EUG at follow-up.  
 
Statistical analysis  
Baseline and follow-up characteristics were compared between groups using Mann-Whitney 
U or Kruskal-Wallis analyses for continuous variables and Chi squared tests for categorical 
variables. Post-hoc analyses were performed using Tukey-Kramer tests with correction for 
multiple pairwise comparisons. Multiple regression models were used to assess associations 
of clinical variables with iPHG, or pPHG, using pEUG as the referent group. In assessing 
potential risk factors for PHG, centre was included in the regression model as a random-
effects variable and the potential risk factors as fixed-effects variables 2. Multiple regression 
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models were used also to adjust for baseline age (40-49 years, 50-59 years, 60-69 years, ≥70 
years) and chronic illness (0, 1, ≥2 illnesses). 
 
Results from linear regression models are presented as regression coefficients (for 
standardised variables) with 95% confidence intervals (CI) and from logistic regression 
models as odds ratios (OR) with CI. All statistical analyses were conducted using STATA 
version 13 (StataCorp, College Station, TX). 
 
Results  
 
Gonadal status transition 
Of the 3,369 men that participated in EMAS, 1,991 men made up the main analytical sample 
after exclusion of those with known pituitary, testicular or adrenal disease (n=94), failure to 
attend for follow-up assessment (n=575), missing T or LH data (n=122), and SHG (n=369, 
Figure 1). Those currently using steroid hormones (n=11 at baseline, n=17 at follow-up), 
gonadotrophin-releasing hormone analogues (n=9 at baseline, n=3 at follow-up), anti-
androgens (n=45 at baseline, n=31 at follow-up), 5-alpha reductase inhibitors (n=38 at 
baseline, n=46 at follow-up) and strong opioids (n=13 at baseline, n=4 at follow-up) were 
excluded also. Compared to the main analytical sample, men lost to follow-up (n=407) were 
older, had higher BMI, higher smoking prevalence, higher HOMA-IR, worse physical and 
cognitive function and had more illnesses (Supplemental Table 1). This was the case also for 
men who died (n=168) with the exception of no difference, compared to the main analytical 
sample, in BMI or HOMA-IR.  
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Amongst the 1,991 men in the analytical sample, 1,942 (97.5%) had pEUG and 22 (1.1%) 
developed PHG giving an annual incidence (95% confidence interval) of 0.24%/year (0.10-
0.58) assuming linearity of PHG development. The prevalence of PHG at follow-up was 
2.1% (n=49). Taking into account the baseline prevalence of PHG of 1.7% (n=54), the 
cumulative prevalence rate of PHG was therefore 3.1% amongst the EMAS cohort. 
 
Of 54 men who had PHG at baseline, 18 (33.3%) were lost to follow-up, had medical 
exclusions or no follow-up hormone data. Of the remainder, 7 died (19.4%). Of the remaining 
men with PHG at baseline who had follow-up data (n=29), 22 (75.9%) continued to have 
PHG at follow-up, 5 (17.2%) reverted to EUG at follow-up and 2 (6.9%) developed SHG. 
 
Cohort Characteristics  
At baseline, age was higher, triglyceride to HDL-cholesterol ratio was higher and SF36 
physical function score was lower in iPHG compared with pEUG men (Table 1). In addition, 
iPHG men had lower cognitive function (DSST). At follow-up, the differences in age, SF36 
physical function score and DSST between the groups persisted, while iPHG men also had 
lower haemoglobin, a lower mean physical function rating (PPT, an objective measure of 
physical function). The prevalence of 2 or more illnesses and cardiovascular disease in the 
iPHG group was greater than that in the pEUG group at baseline and at follow-up. Erectile 
dysfunction was more prevalent in the iPHG group than in pEUG at follow-up, as was 
walking limitation and decreased vigour. Men with pPHG differed significantly from those 
with pEUG in the same parameters (as iPHG) except for the triglyceride to HDL-cholesterol 
ratio at baseline. In addition, men with pPHG had higher BMI and HOMA-IR and lower 
physical activity (PASE) and baseline haemoglobin compared to men with pEUG. Like men 
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with iPHG, those with pPHG had more illnesses and more sexual and physical symptoms 
than pEUG men.  
 
Hormone levels 
Baseline total T in iPHG (13.2 ±2.3 nmol/L) was significantly lower than in pEUG (18.4 ±5.4 
nmol/L, p<0.05, Figure 2). Total T decreased during follow-up to 9.3 ±0.9 nmol/L in iPHG 
men and to 18.1 ±5.4 nmol/L in pEUG men with a greater decline evident for iPHG men 
(mean changes -3.9 ±2.7 nmol/L and -0.3 ±4.1 nmol/L, p<0.05). Total T decreased also in 
pPHG men (from 7.3 ±2.4 nmol/L to 5.9 ±2.9 nmol/L) and, by definition, rose in rPHG men 
(from 9.3 ±1.4 nmol/L to 12.7 ±1.2 nmol/L). Free T was already low in iPHG men (203 ±55 
pmol/L) at baseline and fell by 56 ±23 pmol/L at follow-up. In pEUG men free T was 322 
±80 pmol/L at baseline and fell by only 15 ±70 pmol/L at follow-up. LH in the iPHG men 
was already elevated at baseline (16.5 ±14.0 U/L) but did not increase further at follow-up 
(18.5 ±11.5 U/L, p>0.05) despite the substantial falls in total and free T. Mean LH level in 
pPHG men was elevated (20.2 ±8.7 U/L) at baseline and remained unchanged at follow-up 
(22.1 ±11.7 U/L p>0.05). Similarly, mean LH level in rPHG men was 11.0 ±1.6 U/L at 
baseline and remained elevated at follow-up (14.1 ±5.6 U/L p>0.05, n=5). FSH levels closely 
followed those of LH (results not shown). Mean SHBG levels were similar across all 3 
groups at baseline and follow-up and increased slightly in the pEUG, pPHG and rPHG 
groups. 
 
Risk factors  
In a multiple logistic regression model, the oldest men [>70 years, OR 12.48 (1.27-122.13), 
p=0.030] and those with 2 or more illnesses [OR 4.24 (1.08-16.56), p=0.038] were 
significantly more likely to develop PHG during follow-up (Figure 3, iPHG vs pEUG).  
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Symptoms and functional ratings associated with PHG  
At baseline, men who developed PHG during follow-up (iPHG) had lower sexual thought 
frequency, increased erectile dysfunction, decreased vigour (Figure 4A), lower haemoglobin, 
lower physical function, higher depression score and lower cognitive function than men who 
remained eugonadal (pEUG, Figure 4B). However, only erectile dysfunction and 
haemoglobin changed (worsened) more during follow-up in iPHG men than in pEUG men. 
At follow-up, the prevalences of erectile dysfunction and decreased vigour were greater in the 
iPHG group than in the pEUG group. At follow-up also, men with iPHG had lower 
haemoglobin, lower physical function, higher depression score and lower cognitive function 
than men with pEUG.  
 
After adjustment for age and chronic illness, the only parameters that remained significantly 
associated with iPHG (Figure 4, open symbols) were SF36 physical function score at 
baseline, fall in haemoglobin during follow-up and erectile dysfunction, decreased vigour and 
lower haemoglobin at follow-up. However, the power of these adjusted comparisons is 
limited by the small number of iPHG men due to the low incidence. 
 
Among pPHG men (PHG at baseline and at follow-up), all three sexual symptoms were more 
prevalent at baseline and follow-up in comparison to pEUG men (Figure 5A). Frequency of 
sexual thoughts decreased and erectile dysfunction worsened more in the pPHG. Decreased 
vigour was more prevalent, at baseline and follow-up. Low mood was more prevalent in 
pPHG than in pEUG men at baseline only. Haemoglobin levels were significantly lower, and 
HOMA-IR values significantly higher, in pPHG at baseline and follow-up than in pEUG 
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(Figure 5B). SF-36 Physical Function score, PPT rating and DSST were similarly reduced at 
baseline and follow-up in pPHG, but only PPT rating worsened more.  
 
After adjustment for age and chronic illness, decreased morning erections, haemoglobin and 
increased HOMA-IR at baseline and decreased sexual thoughts, haemoglobin and HOMA-IR 
at follow-up remained significantly associated with pPHG (Figure 5, open symbols). Again, 
the power of these adjusted comparisons is limited by the small number of pPHG men. 
 
Discussion 
 
We describe the natural history of, the predisposing factors for and the clinical features 
associated with biochemically-defined primary hypogonadism in the general population. 
Age-related biochemical PHG is a relatively uncommon entity predominantly affecting men 
over the age of 70 years with multiple illnesses who bear little resemblance to the burgeoning 
population of patients actively seeking testosterone replacement 13.  
 
Natural history of PHG 
The relative rarity of biochemical PHG in the EMAS population was indicated by a baseline 
prevalence of 1.7% and confirmed at follow-up by a prevalence 2.1%, giving an incidence of 
only 0.2%/year. In contrast, SHG is much more common having a baseline prevalence of 
11.5%, and an 8-fold higher incidence of 1.6%/y2,14. These figures cannot be directly 
compared with previously reported incidence of symptomatic hypogonadism of 10% over 9 
years15 and prevalence estimates of >20% for overall hypogonadism in the ageing male 
population1,4,16, since these earlier studies did not make the differentiation between PHG and 
SHG. These prevalence rates were determined after exclusion of men with disease of the 
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pituitary, testis or adrenal glands and of men on medications known to affect androgen levels 
– the real-life prevalence rates are likely to be higher.  
 
Ageing-related PHG appears to be mostly irreversible; T levels returned to normal in only 
4.3%/year. This contrasts with SHG which, in EMAS, had a rate of reversal of 9.7%/year14. 
Of the original 54 men with PHG at baseline, 7 (13.0%) died during the follow-up period, 
which is 2.5-fold higher than in the whole study population. Hence, the state of PHG may 
beckon a serious deterioration in health. This is compatible with our, and others’, previous 
finding that late-onset hypogonadism is associated with substantially increased mortality17,18. 
 
Risk factors for PHG 
Advanced age and multiple chronic illnesses are the factors that most strongly predicted the 
development of iPHG. In this respect PHG differs substantially from the more common SHG 
– obesity predicted SHG, but age and chronic illness did not14. These important and 
consistent differences in the risk factors and natural history between PHG and SHG offer 
useful insights and guidance for clinical decision making in symptomatic older men 
presenting with low T. 
 
There is a large body of evidence showing that T levels decrease with ageing in men, ranging 
in various longitudinal studies from 0.04 to 2.6% per year after the age of 401,16,19-21. 
However, obesity strongly influences the magnitude of decline in T independent of age21. 
There are also data suggesting that T levels can be maintained in highly selected elderly men 
who remain in good health22, making the case that it is not age per se, but ageing-related 
health deterioration that affects T production. The HPT axis is tightly regulated in men5 and 
LH levels are highly responsive to any deficits in Leydig cell function23. Impaired testicular 
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response to LH can be caused by exposure to pro-inflammatory cytokines24-26, arising from 
chronic low grade inflammation27, associated with ageing and chronic illness26. It is well 
known that chronic illnesses associated with inflammation, such as cancer and obesity, are 
associated with multi-level disruption of the HPT axis28. Many younger men with chronic 
illness have, therefore, low T with non-elevated LH level (SHG) due to such multi-level 
disruption. Our finding that chronic illness is a risk factor for PHG, but not SHG14 is 
consistent with recent data showing an independent association between elevated LH with 
cardiovascular disease29 and decreased muscle strength30. One can surmise, therefore, that 
excessive elevation of LH (over and above that associated with ageing per se and independent 
of T) can be regarded as a barometer of poor health in ageing men31. 
 
Endocrinology of PHG 
PHG is characterised by elevation of gonadotrophins that is unable to counteract impaired 
Leydig cell function. Only a relatively small proportion of elderly men develop PHG (vide 
supra) since the increased LH can mobilise sufficient testicular functional reserve to maintain 
T in the normal range in the vast majority, as demonstrated by the large number of men with 
compensated hypogonadism (i.e. normal T and elevated LH)2. In the present prospective 
study, baseline mean LH (16.5 ±14.0 U/L) was already significantly elevated in the iPHG 
men, which is compatible with a protracted compensated state and the successful deferment 
of testicular failure. During follow-up, total T declined significantly (from 13.2 ±2.3 to 8.9 
±2.1 nmol/L) in the iPHG group but LH showed little concurrent change (from 16.5 ±14.0 to 
18.5 ±11.5 U/L). This suggests that the HPT axis had reached the limit of its compensating 
capacity possibly due to a superimposing element of hypothalamic dysfunction23, thereby 
allowing testicular failure to supervene. Development of PHG can therefore be predicted 
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several years before gonadotrophic compensation reaches its limit and T eventually falls into 
the hypogonadal range.  
 
Clinical characteristics of PHG 
The development of biochemical PHG was associated with the development (or worsening) 
of erectile dysfunction, decreased vigour and lower haemoglobin. Many of the observed 
differences (from pEUG) in clinical characteristics were already apparent at baseline in those 
EUG men destined to develop PHG during follow-up. Although only a selection of these 
features remained statistically significant after adjustment for age and health status, there 
appears to be a trend of increasing symptoms and functional deficits across iPHG to pPHG 
(Figures 4 and 5). This trend is concurrent with the progressive decline in T and the duration 
of hypogonadism, although our observational data cannot ascribe causality to these 
associations. Interestingly, these findings tally well with those of the recently published 
Testosterone Trials where transdermal testosterone in older men (≥65 years) with a low T 
(≤9.5nmol/L) had a small to medium positive effect on sexual function and small effect on 
physical function and mood32.  
 
There are a number of potential explanations for the relatively limited number of statistically 
significant associations between the development of biochemical PHG with putative 
‘hypogonadal’ features and functional deficits. The PHG group comprised older men (mean 
age over 65) in whom deteriorating health from chronic diseases gives rise to a multitude of 
symptoms and functional deficits, which overlap with those of androgen deficiency. The 
picture of presumed androgen deficiency in men developing PHG is therefore confounded by 
a background of non-specific features of senescence. The small number of men with iPHG 
and pPHG does not provide adequate statistical power to detect small differences (signals) 
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against the significant prevalence of background (noise) symptoms and deficits (unrelated to 
T levels). In iPHG men, LH was already higher, and their T significantly lower, at baseline, 
than in pEUG men. It can therefore be argued that the iPHG men were already borderline 
‘hypogonadal’, i.e. they had compensated hypogonadism with relatively lower mean total T 
and in particular free T. This may have introduced biases against differentiating the 
characteristics of iPHG from pEUG. Notwithstanding these issues, the finding of associations 
between iPHG and pPHG with sexual symptoms, decreased vigour, physical function and 
haemoglobin suggest that biochemical PHG may identify a small group of men with clinical 
features compatible androgen deficiency.  
 
Strengths and weaknesses 
Strengths of EMAS include the number of participants, the simultaneous measurement of T 
by LC-MS/MS in paired baseline and follow-up samples and the breadth of the phenotypic 
data collected by the standardised instruments across centres and between the phases of the 
study. This provided an unprecedented opportunity to describe the natural history and the 
temporal sequences of the earliest clinical changes associated with the onset of biochemical 
hypogonadism in an unselected cohort of men from the general population. To date, no 
prospective studies have described the clinical features associated with the development of 
PHG.  
 
The main limitation in this analysis is the relatively small number of men developing PHG 
during follow-up - this is unavoidable given the relative rarity of the condition which has not 
been previously described. This may have restricted the power of our analyses to clearly 
differentiate changes that could have been related to androgen deficiency from those due to 
age–related health deterioration. Even with the small number of cases, however, some 
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clinically useful insight has been captured. Other limitations in EMAS have been described 
previously6,7. The mortality-adjusted retention rate of 86.2% may have introduced an 
unmeasured survivor bias, but this potential censoring of men with lower T or higher LH 
would have improved the validity of our internal comparisons. The relatively high attrition 
rate in the pPHG group may have mitigated against capturing a more consistent picture of the 
progression of clinical features of hypogonadism from iPHG. The follow-up period of 4.3 
years is a relatively short time in which to capture the more subtle or gradual changes in signs 
and symptoms of androgen deficiency. At both study phases, only a single blood sample was 
available for determination of hormone levels. Multiple blood sample collection is 
impractical in large epidemiological surveys1,15 such as ours.  Several studies have confirmed 
that T levels within the same individual do not fluctuate significantly when measured serially 
over several months33-36. It is therefore unlikely that single hormone determination in the 
present study would have introduced substantial misclassification of gonadal status. The fact 
that the vast majority of EMAS participants remained eugonadal attests to this. The 
consistency of higher LH between baseline and follow-up and the parallel changes in FSH 
also adds to the validity of the present results.  
 
In conclusion, we have shown that only a small proportion (0.2%/year) of older men develops 
biochemical primary testicular failure, with the main risk factors being age >70 years and 
chronic illnesses. Concurrently, these men experienced worsening sexual and physical 
impairments with a fall in haemoglobin. However, not all clinical features suggestive of 
androgen deficiency could be unequivocally attributed to the development of primary 
hypogonadism due to various confounding factors associated with ageing. The present 
findings support further research, including the conduct of additional RCTs of sufficient size 
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and duration, to rigorously investigate both benefits and risks of hormone replacement in 
well-defined groups of older symptomatic men with low T. 
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Figure Legends: 
 
Figure 1: Flowchart of Participants  
pEUG, persistent EUGonadism; pPHG, persistent Primary HypoGonadism; iPHG, incident 
Primary HypoGonadism; rPHG, reversed Primary HypoGonadism 
*Men with secondary hypogonadism have been described previously – see Rastrelli, G. et al 
(2015). J Clin Endocrinol Metab 100, 3172-3182 
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Figure 2: Testosterone, LH and SHBG Levels in relation to Gonadal Status at Baseline and 
Follow-up  
Baseline and follow-up hormone concentrations are expressed as means and as standard 
errors of the mean (SEM). Data in the groups were compared, and p values were generated, 
using Kruskal-Wallis analyses and Tukey-Kramer post-hoc analyses to permit correction for 
multiple pairwise comparisons.  
*, p<0.05; a, follow-up hormone levels in this group differed significantly from the baseline 
hormone levels in the same group when analysed using the Wilcoxon Signed Ranks Test.  
pEUG, persistent EUGonadism; iPHG, incident Primary HypoGonadism; rPHG, recovery 
from Primary HypoGonadism.  
The horizontal dotted lines represent the thresholds above or below which values are 
considered abnormal.  
 
Figure 3: Potential Risk Factors for Primary Hypogonadism 
Data are expressed as odds ratio (symbol) ± 95% confidence interval (error bars). Odds ratios 
and p values were determined in the left panel using single independent variables 
(unadjusted) binary logistic regression analyses. Odds ratios and p values were determined in 
the right panel using multiple binary logistic regression analyses including all the potential 
risk factors listed in the same model. 
*, p<0.05; **, p<0.01.  
 
Figure 4: Relationships between Incident Primary Hypogonadism with Symptoms and 
Functional Ratings 
Categorical data are expressed as odds ratios (symbol) ± 95% confidence intervals (error 
bars). Continuous data are expressed as standardized regression coefficients (symbol) ±  95% 
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confidence intervals (error bars). Regression coefficients, odds ratios and p values were 
determined using regression analyses comparing incident PHG to the referent group of 
persistent eugonadism. 
The statistical analysis was first carried out without adjustment () and then with adjustment 
for baseline age and chronic illness using multiple regression analyses (). 
*, p < 0.05: **, p < 0.01; ***, p < 0.001. 
A) The odds ratios for the prevalence of symptoms at baseline are shown in the left panel and 
for the prevalence at follow-up are shown in the right panel. The middle panel shows the 
odds ratios for the incidence or worsening of symptoms.  
B) The standardized regression coefficients for baseline functional rating values are shown 
in the left panel, for follow-up values in the right panel and for the percentage change in 
values in the middle panel.  
 
Figure 5: Relationships between Persistent Primary Hypogonadism with Symptoms and 
Functional Ratings 
Categorical data are expressed as odds ratios (symbol) ± 95% confidence intervals (error 
bars). Continuous data are expressed as standardized regression coefficients (symbol) ±  95% 
confidence intervals (error bars). Regression coefficients, odds ratios and p values were 
determined using regression analyses comparing incident PHG to the referent group of 
persistent eugonadism. 
The statistical analysis was first carried out without adjustment () and then with adjustment 
for baseline age and chronic illness using multiple regression analyses (). 
*, p < 0.05: **, p < 0.01; ***, p < 0.001. 
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A) The odds ratios for the prevalence of symptoms at baseline are shown in the left panel and 
for the prevalence at follow-up are shown in the right panel. The middle panel shows the 
odds ratios for the incidence or worsening of symptoms.  
B) The standardized regression coefficients for baseline functional rating values are shown 
in the left panel, for follow-up values in the right panel and for the percentage change in 
values in the middle panel.  
 
 
Table 1. Comparison of Baseline and Follow-Up Characteristics in Men with Incident and 
Persistent Primary Hypogonadism and those with Persistent Eugonadism  
 Baseline Follow-Up 
Parameter pEUG iPHG pPHG P1 pEUG iPHG pPHG P2 
N 1,942 22 22  1,942 22 22  
Age, years 
58.3 
±10.5 
66.9 
±11.1a 
71.0 
±8.8a 
<.001 
62.7 
±10.4i 
71.4 
±11.0ai 
75.4 
±8.7ai 
<.001 
BMI, kg/m2 
27.1 
±3.8 
28.1 
±3.1 
30.1 
±4.2a 
<.001 
27.2 
±3.9i 
28.1 
±3.6 
29.6 
±5.0a 
0.043 
Smoking, n (%) 
398 
(20.7) 
7 (31.8) 2 (9.5) 0.196 
344 
(18.3)i 
6 (28.6) 2 (9.5) 0.278 
Frequent 
Alcohol, n (%) 
481 
(24.9) 
5 (22.7) 
5 
(22.7) 
0.948 
596 
(35.2)i 
9 
(45.0)i 
5 (27.8) 0.529 
Pre-degree 
Education, n 
(%) 
1,336 
(70.3) 
13 
(61.9) 
18 
(81.8) 
0.349 --- --- --- --- 
Living with 
Partner, n (%) 
1,537 
(84.8) 
14 
(77.8) 
16 
(84.2) 
0.713 --- --- --- --- 
Trig/HDL 
1.1 
±1.2 
1.3 
±1.0a 
1.9 
±2.4 
0.011 
1.2 
±2.3 
1.1 
±0.8 
2.6 
±4.4a 
0.018 
HOMA-IR 
2.8 
±3.6 
3.3 
±3.1 
7.0 
±7.8ab 
<.001 
2.8 
±3.0 
3.0 
±1.6 
7.0 
±8.4ab 
<.001 
Hb, g/L 
150 
±11 
146 ±9 
141 
±13a 
0.001 
150 
±11 
139 
±13a 
139 
±14a 
<.001 
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PASE score 
207 
±88 
181 
±108 
142 
±92a 
0.004 
183 
±94i 
164 
±112 
127 
±82a 
0.016 
PPT rating 
24.3 
±2.4 
23.2 
±2.8 
23.1 
±2.1 
0.010 
23.8 
±2.5i 
22.0 
±2.7ai 
21.5 
±2.4ai 
<.001 
SF-36 physical 
function 
51.1 
±7.5 
44.7 
±9.7a 
46.1 
±9.1a 
<.001 
50.5 
±8.2i 
44.8 
±9.5a 
42.5 
±11.3a 
<.001 
BDI 
6.4 
±6.0 
9.4 
±6.6 
5.8 
±5.5 
0.034 
6.2 
±6.4 
9.5 
±6.4 
5.1 
±4.4 
0.023 
DSST 
28.9 
±8.4 
22.9 
±9.3a 
21.9 
±9.1a 
<.001 
27.9 
±8.9i 
22.4 
±9.9a 
19.0 
±7.9a 
<.001 
≥1 illness, n 
(%) 
739 
(38.1) 
15 
(68.2)a 
19 
(86.4)a <.001 
1,030 
(53.0)i 
17 
(77.3) 
19 
(86.4)a 0.001 
≥2 illnesses, n 
(%) 
287 
(19.3) 
9 
(56.3)a 
7 
(70.0)a <.001 
561 
(38.1)i 
14 
(73.7)a 
12 
(80.0)a <.001 
Diabetes, n (%) 
107 
(5.6) 
3 (13.6) 
3 
(14.3) 
0.067 
127 
(6.7)i 
4 (19.1) 4 (19.1) 0.008 
CVD, n (%) 
576 
(30.1) 
13 
(59.1)a 
15 
(71.4)a <.001 
740 
(40.6)i 
14 
(70.0)a 
13 
(68.4)a 0.002 
Decreased 
morning 
erections, n (%) 
623 
(32.9) 
10 
(52.6) 
15 
(75.0)a <.001 
616 
(34.4)i 
8 (53.3) 
13 
(72.2)a 0.001 
Decreased 
sexual 
thoughts, n (%) 
430 
(22.7) 
9 (45.0) 
12 
(60.0)a <.001 
480 
(26.6)i 
8 (47.1) 
14 
(73.7)a <.001 
Erectile 
dysfunction, n 
(%) 
466 
(24.8) 
9 (45.0) 
13 
(65.0)a <.001 
537 
(31.0)i 
11 
(73.3)a 
13 
(76.5)a <.001 
Limited 
walking >1km, 
n (%) 
31 
(1.6) 
0 (0.0) 
5 
(22.7)a <.001 
73 
(3.9)i 
3 
(15.8)a 
5 
(22.7)a <.001 
Decreased 
vigorous 
activity, n (%) 
371 
(19.3) 
8 (40.0) 
9 
(40.9)a 0.003 
448 
(24.0)i 
12 
(60.0)a 
12 
(54.6)a <.001 
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Unable to bend, 
n (%) 
82 
(4.3) 
5 
(25.0)a 
4 
(18.2)a <.001 
94 
(5.0) 
2 (10.0) 1 (4.6) 0.599 
Fatigue, n (%) 
73 
(3.8) 
2 (10.0) 1 (4.6) 0.351 
81 
(4.3) 
1 (5.0) 1 (4.8) 0.984 
Low mood, n 
(%) 
71 
(3.7) 
2 (10.5) 
3 
(14.3)a 0.014 
72 
(3.9) 
1 (5.0) 2 (9.5) 0.412 
Loss of energy, 
n (%) 
76 
(3.9) 
2 (10.5) 0 (0.0) 0.216 
106 
(5.6)i 
2 (10.0) 2 (9.1) 0.560 
Data are expressed as mean ± standard deviation for continuous variables or as number 
(percentage) for binary categorical variables. 
Abbreviations: pEUG, T≥10.5nmol/L at both baseline and follow-up; iPHG, T≥10.5nmol/L 
at baseline, T<10.5nmol/L at follow-up and LH>9.4U/L at follow-up; pPHG, T<10.5nmol/L 
and LH >9.4U/L at both baseline and follow-up; BMI, Body Mass Index; HOMA-IR, 
HOmeostatic Model of Insulin Resistance; Hb, haemoglobin SF-36, PASE, Physical Activity 
Scale for the Elderly; PPT, Physical Performance Test; Short-Form 36 questionnaire; DSST, 
Digital Symbol Substitution Test; BDI, Beck Depression Inventory; MetS, Metabolic 
Syndrome; CVD, CardioVascular Disease. 
1. P values were calculated using baseline parameters and either Kruskal-Wallis analyses for 
continuous variables or the Chi squared test for categorical variables. 
2. P values were calculated using follow-up parameters and either Kruskal-Wallis analyses 
for continuous variables or the Chi squared test for categorical variables. 
a
 Data differ significantly (p<0.05) from those in the pEUG group on post-hoc analysis using 
Tukey-Kramer for continuous variables or the z-test for categorical variables with correction 
for multiple pairwise comparisons. 
b
 Data differ significantly (p<0.05) from those in the iPHG group on post-hoc analysis using 
Tukey-Kramer for continuous variables or the z-test for categorical variables with correction 
for multiple pairwise comparisons. 
i
 Data differ from baseline values within the same group when analysed using Wilcoxon 
Signed Ranks Test or the McNemar test. 
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